Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,055.0
-68.2 (-2.18%)

 

  • STI Straits Times Index
    3,055.0
    -68.2 (-2.18%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,582.5
    4.9 (0.31%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,027.6
    308.9 (1.11%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,490.4
    60.8 (1.77%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    28,084.5
    636.5 (2.32%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    5,975.8
    -
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 3,365.6M
  • Value: 3,210.3M
  • Rise: 58
  • Fall: 386
  • Unch: 328

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Shen Yao0.007-0.002
Sembcorp Marine0.179-0.012
Oceanus^0.033-0.003
Genting Sing0.785-0.025
YZJ Shipbldg SGD1.410-0.050
Golden Agri-Res0.250-0.025
Singtel2.320-0.090
Frasers Property1.160-0.040
ThaiBev0.670-0.025
Jiutian Chemical0.091-0.007

World Indices

World Indices
Name Last Change
Nasdaq 13,430.0 +305.0
HSI 28,027.6 +308.9
HSCEI 10,405.0 +65.0
Jakarta 5,975.8
Nikkei 225 28,084.5 +636.5
SSE Comp 3,490.4 +60.8
Shanghai A 3,658.5 +63.8
Shanghai B 250.2 +2.5
KOSPI 3,153.3 +31.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Lonza LONZA GROUP LTD
Quotes 10 Minutes Delayed. Updated at 14 May 2021 07:12
Last (SGD): 79.970 Change: - High: - Remarks: -
Change (%): - Low: -
Open - Yesterday's Close 79.970
Buy Price - Sell Price -
Buy Volume ('000) - Sell Volume ('000) -
Cumulative Volume ('000) - Cumulative Value -
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 17.53581 Trailing EPS (SGD) e 17.53581 NAV (SGD) b 136.8358
PE a 4.560 Trailing PE f 4.560 Price / NAV b 0.5844
Dividend (SGD) d 4.497300 Cash In Hand (SGD) g 9.9887 Issued & Paid-up Shares c 74,289,000
Dividend Yield (%) d 5.624 Price / Cash In Hand g 8.006 Treasury Shares h 180,000
Beta - 75 Daysi - R-Squared - 75 Days(%)i - Market Cap (M) 5,940.891
Beta - 500 Daysi - R-Squared - 500 Days (%)i - Enterprise Value (M) 10,669.053
Piotroski F Score 6 Exchange Code O6Z Par Value ( CHF ) 1.00000
52 Weeks Volatility (%) 0.0 6-Month VWAP n.a. Free Float (%) 99.9
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Manufacturing - Biotechnology
Category Classification Foreign Listing (Others) / Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 27 Jul 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 27 Jul 2020.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Lonza SGX 5,940.891 4.560 4.560 0.5844 5.624
Industry Biotechnology SGX 2,992.255 4.594 4.594 0.5877 5.583
Foreign Listing (Others) SGX 7,517.692 22.906 15.489 1.7774 1.768
Medical & Biotechnology SGX 932.022 19.045 18.137 1.3281 2.120
Local Peer Suntar Eco-City SGX 43.618 1737.500 1744.741 2.4090 -
Global Peer AMGEN INC NASDAQ 144,431.385 19.883 20.386 15.4737 2.563
Global Peer AMGEN-T HKEx 1,011,789.594 17.959 18.421 13.9429 2.837
Global Peer CSL LTD ASX 126,377.722 40.295 33.207 11.9593 1.057
Global Peer GILEAD SCIENCES INC NASDAQ 85,948.955 698.787 285.545 4.5351 3.968
Global Peer MODERNA INC NASDAQ 64,798.589 - 108.329 16.8834 -
Global Peer WUXI BIO HKEx 439,596.059 231.634 231.636 18.0296 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 56,197.220 20.724 20.346 6.2579 -
Global Peer ILLUMINA INC NASDAQ 55,630.380 84.802 88.302 11.3024 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 55,042.746 15.667 13.748 4.5957 -
Global Peer BIONTECH SE SPON ADS EACH REP 1 ORD SHS NASDAQ 46,558.003 2,687.439 32.032 15.7222 -
Other Global Peers BIOGEN INC (NASDAQ), ALEXION PHARMACEUTICAL INC (NASDAQ), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), BEIGENE (HKEx), SEAGEN INC (NASDAQ), SINO BIOPHARM (HKEx), INCYTE CORPORATION (NASDAQ), EXACT SCIENCES CORP (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), 10X GENOMICS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ZAI LAB-SB (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), NOVAVAX INC (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), EXELIXIS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), GENSCRIPT BIO (HKEx), BLUEPRINT MEDICINES CORP (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), JOINN (HKEx), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), ALKERMES PLC (NASDAQ), RECURSION PHARMACEUTICALS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), OLINK HLDG AB SPON ADS EACH REP 1 ORD SHS (NASDAQ), ARVINAS INC (NASDAQ), KINTOR PHARMA-B (HKEx), INTRA-CELLUAR THERAPIES INC (NASDAQ), INSMED INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), 3SBIO (HKEx), VERACYTE INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), ORGANOGENESIS HOLDINGS INC (NASDAQ), NUVATION BIO INC (NYSE), XENCOR INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), INSTIL BIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ALPHAMAB-B (HKEx), NGM BIOPHARMACEUTICALS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), DECIPHERA PHARMACEUTICALS INC (NASDAQ), FIBROGEN INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), SORRENTO THERAPEUTICS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), JACOBIO-B (HKEx), SEER INC (NASDAQ), MACROGENICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), OCUGEN INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), KURA ONCOLOGY INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), VIVA BIOTECH (HKEx), ALLOVIR INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), REGENXBIO INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), BIOATLA INC (NASDAQ), IMMUNOVANT INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), UNIQURE N.V. (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), ASCENTAGE-B (HKEx), VALNEVA SE SPON ADS EACH REPR 2 ORD SHS (NASDAQ), PRECIGEN INC (NASDAQ), JW THERAP-B (HKEx), HERON THERAPEUTICS INC (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), EDGEWISE THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), IMMUNOGEN INC (NASDAQ), POLYNOVO LIMITED (ASX), PROTAGONIST THERAPEUTICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), FRONTAGE (HKEx), ATARA BIOTHERAPEUTICS INC (NASDAQ), CURIS INC (NASDAQ), AVID BIOSERVICES INC (NASDAQ), IMUGENE LIMITED (ASX), COHERUS BIOSCIENCES INC (NASDAQ), OMEROS CORP (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), SHATTUCK LABS INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), CORTEXYME INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), MIMEDX GROUP INC (NASDAQ), HUMANIGEN INC (NASDAQ), AFFIMED N V (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PLIANT THERAPEUTICS INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), VAXCYTE INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), JHBP-B (HKEx), EPIZYME INC (NASDAQ), NKARTA INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), TRILLIUM THERAPEUTICS INC (NASDAQ), MESOBLAST LTD (ASX), PERSONALIS INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), MERUS B V (NASDAQ), PASSAGE BIO INC (NASDAQ), TELIX PHARMACEUTIC (ASX), MERIDIAN BIOSCIENCE INC COM (NASDAQ), VAXART INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), AKOYA BIOSCIENCES INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CHEMOCENTRYX INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), VOR BIOPHARMA INC (NASDAQ), AGENUS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), CHIMERIX INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), IMMATICS N V (NASDAQ), ATHIRA PHARMA INC (NASDAQ), ARDELYX INC (NASDAQ), COMPUGEN (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), IKENA ONCOLOGY INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), KADMON HLDGS INC (NASDAQ), INHIBRX INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), IVERIC BIO INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), AKEBIA THERAPEUTICS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), XBIOTECH INC (NASDAQ), VERASTEM INC (NASDAQ), ALTIMMUNE INC (NASDAQ), DPHARMA (Bursa), VIKING THERAPEUTICS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), GERON CORP (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), ANTEOTECH LIMITED (ASX), ASCLETIS-B (HKEx), MOLECULAR TEMPLATES INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), AKOUOS INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), ADICET BIO INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), SINOMAB BIO-B (HKEx), 22ND CENTURY GROUP INC (NYSE American), AVROBIO INC (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), SESEN BIO INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), ESSEX BIO-TECH (HKEx), SOLID BIOSCIENCES INC (NASDAQ), OPTHEA LIMITED (ASX), ATHERSYS INC (NASDAQ), ONCORUS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), LINEAGE CELL THERAPEUTICS INC (NYSE American), OUTLOOK THERAPEUTICS INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), ATRECA INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), PORTAGE BIOTECH INC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), XOMA CORP (NASDAQ), LEE'S PHARM (HKEx), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), LAVA THERAPEUTICS NV (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), BELLUS HEALTH INC (NASDAQ), RAIN THERAPEUTICS INC (NASDAQ), VIRACTA THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), NEXT SCIENCE LTD (ASX), KAMADA LTD (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), TREVENA INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), IMMUTEP LTD (ASX), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), CHIASMA INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), CABALETTA BIO INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), NEXTCURE INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), NANOVIRICIDES INC (NYSE American), IMMUNOME INC (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), CEL-SCI CORP (NYSE American), LARIMAR THERAPEUTICS INC (NASDAQ), MEDICINOVA INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), VERA THERAPEUTICS INC. (NASDAQ), MARKER THERAPEUTICS INC (NASDAQ), BIOVIE INC (NASDAQ), CHEMOMAB THERAPEUTICS LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), MEDICENNA THERAPEUTICS CORP (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), SAVARA INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), SYNLOGIC INC (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), BIONOMICS LTD (ASX), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), IMV INC (NASDAQ), EQUILLIUM INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), CONTRAFECT CORP (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), VIRIDIAN THERAPEUTICS INC (NASDAQ), INMUNE BIO INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ENZO BIOCHEM INC (NYSE), EVOGENE LTD (NASDAQ), BIOMX INC (NYSE American), IBIO INC (NYSE American), CATALYST BIOSCIENCES INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), CONCERT PHARMACEUTICALS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), MINERVA NEUROSCIENCES INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), ORGENESIS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), INFLARX N V (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), OTONOMY INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), RECRO PHARMA INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GAIN THERAPEUTICS INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), LONGEVERON INC (NASDAQ), ARMATA PHARMACEUTICALS INC (NYSE American), ARAVIVE INC (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AIM IMMUNOTECH INC (NYSE American), TRACON PHARMACEUTICALS INC (NASDAQ), LEAF RESOURCES LTD (ASX), LEAP THERAPEUTICS INC (NASDAQ), METACRINE INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), UNI-BIO GROUP (HKEx), PALATIN TECHNOLOGIES INC (NYSE American), COHBAR INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), PRECIPIO INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), CHIMERIC THERAPEUTICS LTD (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), SYNTHETIC BIOLOGICS INC (NYSE American), MONOPAR THERAPEUTICS INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), CYCLACEL PHARMACEUTICALS INC (NASDAQ), VACCINEX INC (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), REGENT PACIFIC (HKEx), AZURRX BIOPHARMA INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), BIOCARDIA INC (NASDAQ), ADVAXIS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), CT ENTERPRISE (HKEx), OPIANT PHARMACEUTICALS INC (NASDAQ), GENETIC TECHNOLOGIES (ASX), IDERA PHARMACEUTICALS INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), PRESCIENT THERAPEUTICS LIMITED (ASX), WINDTREE THERAPEUTICS INC (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), INDIA GLOBALIZATION CAPITAL INC (NYSE American), CATABASIS PHARMACEUTICALS INC (NASDAQ), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), INVEX THERAPEUTICS LTD NPV (ASX), BIO-PATH HOLDINGS INC (NASDAQ), AUSTRALIAN PRIMARY HEMP LTD (ASX), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), SOLIGENIX INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), HISTOGEN INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), MEMPHASYS LTD (ASX), GEOVAX LABS INC (NASDAQ), RHINOMED LIMITED (ASX), PATRYS LIMITED (ASX), ORAGENICS INC (NYSE American), BIOTRON (ASX), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), PALISADE BIO INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), ADALTA LTD (ASX), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), BIOSINO BIO-TEC (HKEx), REGENEUS LTD (ASX), AMPLIA THERAPEUTICS LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), CONSTELLATION TECHNOLOGIES LTD (ASX), BRIACELL THERAPEUTICS CORP (NASDAQ), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SENESTECH INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), CRYOSITE (ASX), HOLISTA COLLTECH LIMITED (ASX), NANOLLOSE LTD (ASX), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), NOVABAY PHARMACEUTICALS INC (NYSE American), ANATARA LIFESCIENCES LTD (ASX), HAO WEN HLDGS (HKEx), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

Not enough data to show total shareholder returns
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 79.970 - 79.970 Change From 1 Year Low - % Change From 1 Year Low (%) -
Change From 1 Year High - % Change From 1 Year High (%) -
2 Years Range 79.970 - 79.970 Change From 2 Years Low - % Change From 2 Years Low (%) -
Change From 2 Years High - % Change From 2 Years High (%) -
5 Years Range 79.970 - 79.970 Change From 5 Years Low - % Change From 5 Years Low (%) -
Change From 5 Years High - % Change From 5 Years High (%) -
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Lonza Group Ltd is a corporation incorporated under the laws of Switzerland and has been listed on the SIX Swiss Exchange (the “SIX”) since November 1999.Lonza is a supplier to the pharmaceutical, healthcare and life sciences industries with products and services spanning from research to final product manufacture to meet customers' needs. The products Lonza manufacture for the life sciences industry can be characterised as very complex molecules which are manufactured in a highly regulated environment and will end up in the body of human beings or animals.Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. The Group has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. The Group provides cell-based research, endotoxin detection and cell therapy manufacturing. The Group is also a provider of high value chemicals and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.To provide optimal support to its customers, the Group is organized into three business divisions, namely, Custom Manufacturing, Life Science Ingredients and Bioscience, which focus on specific sets of customers and their needs.

IPO Performance

Listing Date 21 Oct 2011 Full Subscription Rate (x) -
No of Placement Shares (M) - No of Public Offer Shares (M) - Public Offer Subscription Rate (x) -
IPO Price (SGD) a - First Day Close (SGD) a 79.970 First Week Close (SGD) a 79.970
Current vs IPO Price (%) - First Day Gain (%) - First Week Gain (%) -
Notes:
  1. Adjusted for the following: IPO Price is not available as there are no issue of Shares under the Listing by way of Introduction.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Dec 2020 Part 1(0.46 MB)
Part 2(13.07 MB)
Annual Report 2019 Dec 2019 Part 1(0.15 MB)
Part 2(18.45 MB)
Annual Report 2018 Dec 2018 Part 1(7.67 MB)
Annual Report 2017 Dec 2017 Part 1(10.98 MB)
Annual Report 2016 Dec 2016 Part 1(7.93 MB)
Annual Report 2015 Dec 2015 Part 1(1.90 MB)
Part 2(2.28 MB)
Annual Report 2014 Dec 2014 Part 1(3.90 MB)
Part 2(6.06 MB)
Annual Report 2013 Dec 2013 Part 1(3.42 MB)
Annual Report 2012 Dec 2012 Part 1(3.87 MB)
Annual Report 2011 Dec 2011 Part 1(5.01 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
14 May 2021 79.970 79.970 79.970 79.970 - -
12 May 2021 79.970 79.970 79.970 79.970 - -
11 May 2021 79.970 79.970 79.970 79.970 - -
10 May 2021 79.970 79.970 79.970 79.970 - -
07 May 2021 79.970 79.970 79.970 79.970 - -
06 May 2021 79.970 79.970 79.970 79.970 - -
05 May 2021 79.970 79.970 79.970 79.970 - -
04 May 2021 79.970 79.970 79.970 79.970 - -
03 May 2021 79.970 79.970 79.970 79.970 - -
30 Apr 2021 79.970 79.970 79.970 79.970 - -
29 Apr 2021 79.970 79.970 79.970 79.970 - -
28 Apr 2021 79.970 79.970 79.970 79.970 - -
27 Apr 2021 79.970 79.970 79.970 79.970 - -
26 Apr 2021 79.970 79.970 79.970 79.970 - -
23 Apr 2021 79.970 79.970 79.970 79.970 - -
22 Apr 2021 79.970 79.970 79.970 79.970 - -
21 Apr 2021 79.970 79.970 79.970 79.970 - -
20 Apr 2021 79.970 79.970 79.970 79.970 - -
19 Apr 2021 79.970 79.970 79.970 79.970 - -
16 Apr 2021 79.970 79.970 79.970 79.970 - -
15 Apr 2021 79.970 79.970 79.970 79.970 - -
14 Apr 2021 79.970 79.970 79.970 79.970 - -
Summary
Current 2 Weeks
(30 Apr 2021 to 14 May 2021)
79.970 79.970 79.970 79.970 - -
Previous 2 Weeks
(16 Apr 2021 to 29 Apr 2021)
79.970 79.970 79.970 79.970 - -
4 Weeks from
(18 Mar 2021 to 15 Apr 2021)
79.970 79.970 79.970 79.970 - -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.